Krystal Biotech, Inc.
KRYS
$150.27
-$0.06-0.04%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 96.04M | 88.18M | 91.14M | 83.84M | 70.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 96.04M | 88.18M | 91.14M | 83.84M | 70.28M |
| Cost of Revenue | 7.17M | 5.03M | 4.95M | 6.68M | 6.01M |
| Gross Profit | 88.88M | 83.16M | 86.19M | 77.16M | 64.28M |
| SG&A Expenses | 35.16M | 32.72M | 31.29M | 28.71M | 27.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.74M | 52.01M | 49.76M | 48.91M | 49.22M |
| Operating Income | 39.31M | 36.18M | 41.38M | 34.93M | 21.07M |
| Income Before Tax | 46.78M | 43.60M | 48.61M | 29.77M | 16.05M |
| Income Tax Expenses | 8.44M | 7.86M | 3.13M | 2.59M | 477.00K |
| Earnings from Continuing Operations | 38.33M | 35.73M | 45.48M | 27.18M | 15.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.33M | 35.73M | 45.48M | 27.18M | 15.57M |
| EBIT | 39.31M | 36.18M | 41.38M | 34.93M | 21.07M |
| EBITDA | 39.62M | 36.62M | 41.64M | 35.27M | 22.37M |
| EPS Basic | 1.33 | 1.24 | 1.58 | 0.95 | 0.54 |
| Normalized Basic EPS | 1.01 | 0.95 | 1.06 | 0.92 | 0.62 |
| EPS Diluted | 1.29 | 1.20 | 1.53 | 0.91 | 0.53 |
| Normalized Diluted EPS | 0.98 | 0.91 | 1.02 | 0.88 | 0.60 |
| Average Basic Shares Outstanding | 28.91M | 28.82M | 28.76M | 28.72M | 28.60M |
| Average Diluted Shares Outstanding | 29.75M | 29.87M | 29.88M | 29.90M | 29.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |